Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences, Inc. (NASDAQ:CHRS) presented preclinical data for CHS-1000, a novel anti-ILT4 antibody, at the 2024 AACR Annual Meeting. CHS-1000 shows high affinity for ILT4, reverses its immunosuppressive functions, and activates immune cells, suggesting potential to enhance antitumor responses with immunotherapy. CHS-1000 is the first immuno-oncology product developed by Coherus, with an IND submission planned for Q2 2024.
April 08, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coherus BioSciences presented promising preclinical data for CHS-1000, a novel anti-ILT4 antibody, indicating potential in enhancing antitumor responses. The company plans to submit an IND in Q2 2024, marking a significant milestone in its immuno-oncology pipeline.
The positive preclinical data for CHS-1000 suggests a strong potential for Coherus BioSciences in the immuno-oncology field. The planned IND submission for Q2 2024 indicates progress in their pipeline, likely generating investor optimism and potentially impacting the stock price positively in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100